Zalicus (ZLCS) continues its upward trajectory from yesterday, gaining another 3% on the back...


Zalicus (ZLCS) continues its upward trajectory from yesterday, gaining another 3% on the back yesterday's +15% run after saying it's initiated the second of two Phase 2a clinical studies with Z160, its treatment for chronic neuropathic pain.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs